Tumor/Biomarker-Specific Combination Strategies with the RAF/MEK Clamp VS-6766

Time: 4:30 pm
day: Day One Track H

Details:

  • VS-6766 blocks the RAS pathway through a novel RAF/MEK clamp mechanism
  • Rationale for ongoing combination trials with VS-6766 with defactinib or everolimus
  • Novel VS-6766 combinations for tumor/biomarkerspecific patient populations

Speakers: